tbuckley/cabot-search huggingface dataset:
registHER: Baseline characteristics of a cohort of HER2-positive metastatic breast cancer (MBC) patients
Authors: P. Kaufman, M. Mayer, S. Paik, M. Ulcickas Yood, D. Yardley, E. Tan-Chiu, A. M. Brufsky, H. Rugo, D. Tripathy, L. Wang
Journal: Journal of Clinical Oncology (2006)

20095 Background: HER2 is amplified in 25% of breast cancers and is associated with poor survival. registHER captures the natural history, treatment patterns and outcomes in 1000 newly-diagnosed HER2-positive MBC patients (pts) throughout the U.S. This observational study recruits pts in both academic and community centers. Methods: This ongoing prospective cohort study collects clinical, pathologic and treatment data at enrollment, quarterly until death, loss to follow-up or 3 years after the last enrollment. We describe baseline pt and clinical characteristics in registHER compared with HER2-positive MBC pts in the phase III pivotal trial (Slamon DJ, et al. N Engl J Med. 2001;344:783–792). Results: Between December 2003 and September 2005, 813 eligible pts were enrolled at 280 study sites. Most pts were seen at community-based (76%) vs academic (18%) clinics; a few pts did not fall into either category (6%). A comparison of baseline characteristics is shown below. Conclusions: registHER pts tended to have a shorter disease-free interval and more estrogen receptor positive disease than pts in the pivotal trial. Reasons for these differences could reflect trial referral and/or diagnostic testing differences. Fewer registHER patients were white, but other characteristics were similar between the two groups. These findings support the hypothesis that observational studies describe a broad patient population which may not exactly duplicate clinical trials. Within registHER, there was some variation between academic vs community clinics (eg. nodal status and adjuvant therapy). Treatment pattern analyses are ongoing. [Table: see text] [Table: see text]
Current situation of human diphyllobothriasis in Europe
Authors: J Dupouy-Camet, R Peduzzi
Journal: Eurosurveillance (2004)

Diphyllobothriasis, a parasitosis caused by the flatworm Diphyllobothrium latum, is contracted by consuming raw or undercooked freshwater fish. The aim of this study was to evaluate the situation of this parasitosis during the past 20 years in Europe through the analysis of databases and search engines (Medline, Cabi Helminthological abstracts,Yahoo, Google), and through a questionnaire sent to a network of European parasitologists and to microbiological laboratories located on the shores of the large Alpine lakes. This study has shown that several dozen cases have been reported each year in Finland and Sweden, that there have been numerous cases in the French or Italian speaking areas of subalpine lakes, and that sporadic cases only have been observed in Austria, Spain, Greece, Romania, Poland and Norway. Over 30 cases have been identified on the Swiss shores of Lake Maggiore since 1990, and 70 cases on the Swiss and French shores of Lake Leman between 1993 and 2002. Eight to 12% of perch fillets from Lake Leman and 7.8 % of perch from Lake Maggiore were infested with larvae. Contamination sources include marinated fish fillets in northern Europe, 'carpaccio di persico' in northern Italy, and perch and charr consumed raw or undercooked around Lake Leman. Factors allowing the continuation of the parasitic cycle include the continued dumping of wastewater into lakes, yachtsmen who also fish, and a possible animal reservoir.
Serum Lysozyme Levels in Crohn's Disease and Ulcerative Colitis
Authors: E Hylander, N E Hansen, H Karle, S Jarnum
Journal: New England Journal of Medicine (1976)

Serum lysozyme levels were determined in healthy volunteers, patients with Crohn's disease, and patients with ulcerative colitis.The mean concentration in Crohn's disease was signifi- cantly greater than in the other groups.In patients with Crohn's disease, as well as in patients with ulcerative colitis, the lysozyme levels correlated with the severity of the disease process and with the extent of the lesions: the more severe the disease and the more extensive the involvement, the higher the lysozyme levels.However, the lysozyme values of the different groups overlapped considerably.Our results indicate that lysozyme determinations have only limited discriminative value for the diagnosis of Crohn's disease and for determining the severity and the extent of the disease process in the individual patient.
Nitrosoglutathione-generating nitric oxide nanoparticles as an improved strategy for combating Pseudomonas aeruginosa–infected wounds
Authors: Jason Chouake, David Schairer, Allison Kutner, David A Sanchez, Joy Makdisi, Karin Blecher-Paz, Parimala Nacharaju, Chaim Tuckman-Vernon, Phil Gialanella, Joel M Friedman, Joshua D Nosanchuk, Adam J Friedman
Journal: Journal of the American Academy of Dermatology (2013)
Abstract B43: Quantitative PCR and in-situ-hybridization analysis to determine tissue concentration and localization of MRX34
Authors: Desiree Martin, Kevin Kelnar, Andreas G. Bader
Journal: Cancer Research (2016)

Abstract MRX34, a liposomal microRNA (miRNA)-based therapy for cancer, has recently entered clinical trials as a potential first clinical candidate in its class. MRX34 is a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation. Preclinical animal studies have shown that intravenous delivery of MRX34 can increase miR-34 levels in liver tumor cells more than 100-fold when analyzing whole-tissue RNA extracts by quantitative PCR (qPCR). MRX34-induced tumor regression has enhanced the survival of mice by inhibiting the growth of both hepatic and non-hepatic tumors. We have established a chromogenic in situ hybridization (CISH) method to track the cellular location of the miR-34 mimic in tissues after systemic MRX34 administration. In contrast to conventional biodistribution approaches that cannot distinguish between spatial differences in tissue accumulation, CISH in conjunction with microscopy allows the detection of the miRNA mimic on a cellular level and may provide new insights into cell-type specific accumulation. Here, we evaluated the localization and tissue concentrations of systemically delivered MRX34 in mice bearing orthotopic Huh7 tumors by CISH followed by image correlation to a formalin-fixed and paraffin-embedded tissue equivalent, and isolation-free qPCR analysis. Our results show that the CISH procedure is a reproducible and robust assay capable of over 2 logs of miR-34 detection when correlated to qPCR data from matching micro-dissected samples. Systemic MRX34 delivery leads to accumulation of miR-34 mimics in tumor cells with Cmax reached approximately 2 hrs post dosing. In addition, the CISH data reveal how biodistribution data generated from whole-tissue extracts can be biased due to minute impurities and suggests that these methods should be used in combination with CISH for an accurate assessment of tissue concentrations. Citation Format: Desiree Martin, Kevin Kelnar, Andreas G. Bader. Quantitative PCR and in-situ-hybridization analysis to determine tissue concentration and localization of MRX34. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B43.
Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer
Authors: Do-Hoon Kim, Ji-hoon Jung, Seung Hyun Son, Choon-Young Kim, Chae Moon Hong, Jong-Ryool Oh, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn
Journal: Clinical Nuclear Medicine (2015)

The aim of the study was to evaluate the prognostic significance of intratumoral metabolic heterogeneity on pretreatment F-FDG PET/CT in patients with lung cancer who were pathologically N0 (pN0) after curative surgical resection.We examined 119 patients (M/F = 79/40; mean age, 64.6 ± 9.0 years) who had undergone pretreatment F-FDG PET/CT and were diagnosed as pN0 after curative surgery for adenocarcinoma (ADC; n = 67) or squamous cell carcinoma (SQCC; n = 52). Heterogeneity factor (HF) and other metabolic parameters (SUVmax, metabolic tumor volume [MTV] and total lesion glycolysis [TLG]) for the primary lesions were measured, and the results were analyzed for recurrence. The HF, defined as the derivative of the volume-threshold function from 20% to 80%, was computed for primary lesions. Univariate and multivariate analyses for recurrence were performed using the Kaplan-Meier method and using the Cox proportional hazards model.SUVmax, MTV, TLG, and HF were statistically different between patients with ADC and SQCC. Forty-one (34.5%) of 119 patients experienced recurrence (ADC, 25/67 = 37.3% vs. SQCC, 16/52 = 30.8%). Results of univariate analysis indicate that SUVmax, MTV, TLG, and HF in ADC and TLG and HF in SQCC were predictors for recurrence. After adjusting for sex, age, and histological grade in multivariate analysis, high SUVmax, MTV, TLG, and HF in ADC exhibited an association with increased risk of recurrence.Metabolic parameters and heterogeneity of primary tumor on pretreatment F-FDG PET/CT can predict recurrence in pN0 NSCLC patients of ADC type who have undergone curative surgery but not in patients of SQCC type.
Prostatic acid phosphatase.
Authors: R J Ablin
Journal: BMJ (1971)

is in the vicinity of 5,000 blood donations annually, apart from the cost of the associated equipment for the preparation of platelet concentrates and the salary of a technologist over and above the salaries of the blood collection staff necessary.In this country we have available a "mini-exchange" set,3 comprising a needle and tubing connected to one limb of a Ypiece which has a free length of tubing from another limb, and the third limb fits the needle adaptor on the standard giving set.This enables the whole manoeuvre of mini-exchange and transfusion to be carried out with a single venepuncture.-Iam, etc.,
Functional Characterization of L-Selectin Ligands on Human Neutrophils and Leukemia Cell Lines: Evidence for Mucinlike Ligand Activity Distinct From P-Selectin Glycoprotein Ligand-1
Authors: Carroll L. Ramos, McRae J. Smith, Karen R. Snapp, Geoffrey S. Kansas, George W. Stickney, Klaus Ley, Michael B. Lawrence
Journal: Blood (1998)

Recent reports have shown that leukocyte-leukocyte adhesion is dependent on L-selectin and that leukocyte recognition of L-selectin may be mediated by P-selectin glycoprotein ligand-1 (PSGL-1). We show that the specific attachment and rolling of human neutrophils and the leukemia cell lines HL-60 and U937 on immobilized, purified L-selectin under continuous shear stress is only partially inhibited by treatment with the PSGL-1 monoclonal antibody (MoAb), KPL1 (41% to 53% inhibition), suggesting that L-selectin ligand activity in addition to PSGL-1 may mediate myeloid cell rolling on L-selectin. K562 cells cotransfected with cDNAs encoding α(1,3)fucosyltransferase-VII (FucT-VII) and PSGL-1 rolled on L-selectin. Adhesion of FucT-VII-PSGL-1 transfectants to L-selectin was completely blocked by MoAb KPL1, indicating that both L-selectin and P-selectin bind similar sites on PSGL-1. In support of existence of a non–PSGL-1 L-selectin ligand activity on leukocytes, an HL-60 membrane preparation immunodepleted of PSGL-1 supported rolling of L-selectin, but not P-selectin transfectants. Treatment of HL-60 cells with O-sialoglycoprotein endopeptidase inhibited attachment and rolling on L-selectin and P-selectin. However, neuraminidase treatment completely blocked HL-60 rolling on L-selectin, but not P-selectin, suggesting L-selectin and P-selectin ligand activities have different contributions of sialic acid. These findings indicate that myeloid cells express sialylated, O-linked glycoprotein ligand activity independent of PSGL-1 that supports L-selectin–mediated rolling.
Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists
Authors: E Jacobs
Journal: Eurosurveillance (2012)

Preview this article: Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/6/art20084-en-1.gif
CBIO-22DICER AND miRNAs REGULATE GLIOMA STEM CELL CHARACTERISTICS
Authors: Sheila Mansouri, Sanjay Singh, Kelly Burrell, Mira Li, Amir Alamsahebpour, Kenneth Aldape, Gelareh Zadeh
Journal: Neuro-Oncology (2015)

Deregulation of microRNA expression is common in a variety of malignancies, including glioma. Several studies have demonstrated the role of miRNAs in regulating glioma stem cell (GSC) properties. In addition, DICER, which regulates the processing of precursor miRNAs to the mature double-stranded form, is down-regulated in multiple forms of cancer. To determine the role of DICER and miRNA regulation in the development and progression of glioblastoma, we investigated the link between miRNA deregulation and GSC characteristics. Our in vitro studies using GSC 7-2 and U251 glioma cell line demonstrated that decreased DICER expression by shRNA treatment results in a global decrease in expression of miRNAs, the majority of which are tumor suppressor miRNAs such as the let-7 family of miRNAs. DICER knockdown increased proliferation of GSCs, while their “stemness” properties, such as their ability to form neurospheres and the levels of stem cell markers such as Sox2 and Bmi1, decreased upon shDicer treatment. Intracranial injection of GSC 7-2 and U251 cells treated with shDicer resulted in decreased overall survival in xenografted mice. Further analysis of the tumors isolated from these mice demonstrated that DICER knockdown results in a relative increase in tumor cell proliferation, as shown by increased ki-67 labeling (30% Ki67 positive nuclei in shDicer versus 15% in shControl tumors), a decrease in expression of Sox2 (stemness marker; 13% in shDicer versus 31% in shControl tumors), and increase in expression of GFAP (astrocytic differentiation marker). Analysis of data from the Cancer Genome Atlas (TCGA) database suggests that high Dicer expression level is correlated with better prognosis of GBM patients and this supports our in vivo data. Our results highlight the role of DICER and miRNAs as potential regulators of GSC proliferation, stem- versus progenitor-like state, and their potential link to development or progression of glioma tumors.
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity
Authors: Eriko Shikata, Ichiro Ieiri, Shingo Ishiguro, Hironao Aono, Kazuko Inoue, Tomoko Koide, Shigetsugu Ohgi, Kenji Otsubo
Journal: Blood (2003)
Indirect Alkylation of CBA Mouse Liver DNA and RNA by Hydrazine In Vivo. A Possible Mechanism of Action as a Carcinogen&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: A Quintero-Ruiz, L L Paz-Neri, S Villa-Treviño
Journal: JNCI Journal of the National Cancer Institute (1981)

Treatment of inbred CBA mice with hydrazine sulfate, a liver carcinogen, plus [14C]formate or L-[methyl-14C]-methionine as a source of "C1" units, produced [14C]7-methylguanine (7-MG) in liver DNA and RNA. This methylated guanine was identified by its chromatographic characteristics in three different systems: on Sephadex G10, on Dowex 50, and by paper co-chromatography with authentic 7-MG. Mice that received [14C]formate alone showed no 7-MG in their DNA or RNA. In addition, mice treated with L-[methyl-14C]methionine alone showed no 7-MG in their DNA. These results suggest that "indirect" alkylation of nucleic acids is a mechanism of cancer initiation by hydrazine.
Enzymatic Properties of Rat Liver Tumor Mitochondria&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Claude Allard, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Enzymatic Properties of Rat Liver Tumor Mitochondria, Get access Claude Allard, Ph.D. Claude Allard, Ph.D. Montreal Cancer Institute, Research Laboratories, Notre-Dame Hospital, Montreal, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1607–1610, https://doi.org/10.1093/jnci/15.Supplement_5.1607 Published: 01 April 1955
Abstract P3-05-13: Estrogen-independent growth of <i>ESR1</i>-mutant breast cancer cells requires CDK4/6
Authors: F Luo, X Le, R Jeselsohn, M Brown, L Garraway
Journal: Cancer Research (2016)

Abstract A recent breakthrough in cancer treatment has been the development of highly specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. CDK4/6 inhibitors, such as palbociclib, prevent cell cycle progression from growth phase (G1) to the DNA synthesis (S) phase of the cell cycle. Palbociclib, however, is only approved for first-line treatment of patients with estrogen receptor positive (ER+) breast cancer in combination with an aromatase inhibitor, letrozole. Approximately 20% of metastatic breast cancer patients, harbor an activating mutation in the ligand-binding domain (LBD) of the estrogen receptor gene, ESR1, which confers resistance to estrogen deprivation. It is unclear whether tumors harboring these endocrine treatment-associated mutations will also respond to CDK4/6 inhibition. We have found that estrogen-independent growth of ESR1 -mutant breast cancer cells requires CDK4/6. Thus, ESR1-mutant breast cancer cells are sensitive to CDK4/6 inhibition. Mechanistically, ERS1 LBD-mutant cells upregulate key mediators of the G1-S cell cycle transition. Furthermore, the sensitivity of ESR1-mutant breast cancer cells to CDK4/6 inhibition requires RB1. While cells expressing RB1 respond to CDK4/6 inhibition, knockout of RB1 via CRISPRs enables ESR1-mutant breast cancer cells to resist combined estrogen depletion and CDK4/6 inhibition. Our studies suggest that tumors harboring ESR1 LBD mutations and an intact RB1 will respond to combined CDK4/6 inhibition and estrogen deprivation. Citation Format: Luo F, Le X, Jeselsohn R, Brown M, Garraway L. Estrogen-independent growth of ESR1-mutant breast cancer cells requires CDK4/6. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-05-13.
Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study
Authors: Emmi Suomela, Mervi Oikonen, Niina Pitkänen, Ari Ahola-Olli, Johanna Virtanen, Riitta Parkkola, Eero Jokinen, Tomi Laitinen, Nina Hutri-Kähönen, Mika Kähönen, Terho Lehtimäki, Leena Taittonen, Päivi Tossavainen, Antti Jula, Britt-Marie Loo, Vera Mikkilä, Risto Telama, Jorma S.A. Viikari, Markus Juonala, Olli T. Raitakari
Journal: Journal of Hepatology (2016)
A National Public Health Service
Authors: N S Galbraith
Journal: Journal of the Royal Society of Medicine (1981)

The development of the British public health services is briefly reviewed and it is suggested that two types of epidemiologist (Community Physician) are necessary in each locality: one concerned with medical administration and health care planning-the medical administrator, and the other with the prevention of disease-the clinical epidemiologist. A new nation public health service is proposed to revive disease prevention with four main features: (1) A district Clinical Epidemiologist who is a member of the district department of community medicine with responsibility for prevention but with no district administrative duties. (2) A District Epidemiology Unit comprising other appropriate staff. (3) National specialist epidemiology units within the NHS with service roles to support and coordinate the District Clinical Epidemiologists. (4) A national authority within the NHS with responsibility for prevention and for administering the national specialist units.
Association Between Body Mass Index and Parkinson Disease
Authors: Rita Cardoso, Diana Miranda, Joaquim J. Ferreira
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB- MYH11 transcripts
Authors: BA van der Reijden, M Lombardo, HG Dauwerse, RH Giles, D Muhlematter, MJ Bellomo, HW Wessels, GC Beverstock, GJ van Ommen, A Hagemeijer
Journal: Blood (1995)
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
Authors: Duncan Porter, Jurgen van Melckebeke, James Dale, C Martina Messow, Alexander McConnachie, Andrew Walker, Robin Munro, John McLaren, Euan McRorie, Jon Packham, Christopher D Buckley, John Harvie, Peter Taylor, Ernest Choy, Costantino Pitzalis, Iain B McInnes
Journal: The Lancet (2016)
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention
Authors: Akshay Bagai, Deepak L. Bhatt, John W. Eikelboom, G.B. John Mancini, Eric A. Cohen, Ram Vijayaraghavan, Asim N. Cheema, Jacob A. Udell, Joel Niznick, Jean-Francois Tanguay, Subodh Verma, Shamir R. Mehta
Journal: Circulation (2016)

DAPT After ACS What Is the Evidence?8][9] This recommendation is based largely on the duration of treatment in the pivotal P2Y 12 receptor
Gastrointestinal Endoscopy
Authors: John F. Morrissey, Mark Reichelderfer
Journal: New England Journal of Medicine (1991)

GASTROINTESTINAL endoscopy has grown over the past 25 years from a technical curiosity mastered by a handful of physicians to a major component of our health care system. The volume and total cost of gastrointestinal endoscopic procedures have recently been increasing at a rapid rate. A British survey has suggested that upper gastrointestinal endoscopy will soon be performed in 1 percent of the population annually.1 Between 1983 and 1986, Medicare payments to gastroenterologists increased by 72 percent, with payments for procedures accounting for 84 percent of the increase.2 The American Society for Gastrointestinal Endoscopy has expanded rapidly and now has . . .
A Therapeutic Vaccine In Adult T-Cell Leukemia Patients With Autologous Dendritic Cells Pulsed With Peptides Corresponding To Tax-Specific Cytotoxic T Lymphocyte Epitopes
Authors: Tadafumi Iino, Youko Suehiro, Atsuhiko Hasegawa, Nobukazu Watanabe, Ryuji Tanosaki, Atae Utsunomiya, Masao Matsuoka, Takanori Teshima, Koichi Akashi, Naokuni Uike, Jun Okamura, Mari Kannagi
Journal: Blood (2013)